IBMM, Université de Montpellier, CNRS, ENSCM, Montpellier , France.
Acc Chem Res. 2019 Feb 19;52(2):510-519. doi: 10.1021/acs.accounts.8b00591. Epub 2019 Jan 24.
Delivery remains a major obstacle restricting the potential action of small molecular drugs as well as novel biologics which cannot readily enter cells without the help of a vector. A successful active delivery process involves three steps: (a) tagging the drug with a vector, (b) effective trafficking of this [drug-vector] conjugate through biological barriers, and finally (c) controlled drug release. While covalent bond formation and/or supramolecular association is involved in the making of the [drug-vector] conjugate, the final step requires precisely a controlled dissociation in order to trigger drug release. Therefore, in pursuit of smart, effective, and nontoxic delivery systems, it has become widely recognized that control over dynamic self-assembly could unleash the efficacy of artificial vectors. In this Account, I discuss our endeavors, and those of colleagues, in the recent implementation of Dynamic Covalent Chemistry (DCvC) in delivery applications. DCvC exploits reversible covalent reactions to generate covalent systems that can self-fabricate, adapt, respond, and fall apart in a controlled fashion. A privileged set of reversible covalent reactions has emerged in the community working on delivery applications and is based on condensation reactions (imine, acylhydrazone, oxime), and disulfide and boronate ester formations. The latest developments making this chemistry particularly attractive for such a DCvC approach are discussed. The rational justifying the potential of DCvC in delivery is based on the principle that using such reversible covalent reactions afford transient [drug-vector] conjugates which form spontaneously and chemoselectively, then adapt and self-correct their structure during self-assembly and trafficking thanks to the dynamic nature of the reversible covalent bonds, and finally respond to physicochemical stimuli such as pH and redox changes, thereby enabling controlled dissociation and concomitant drug release. For these reasons, DCvC has recently emerged as a leverage tool with growing prospects for advancing toward smarter delivery systems. The implementation of DCvC can follow three approaches that are discussed herein: (1) dynamic covalent bioconjugates, involving the transient covalent conjugation with a vector, (2) dynamic covalent vectors, involving the controlled dynamic and adaptive assembly and disassembly of vectors that complex drugs through supramolecular association, and (3) dynamic covalent targeting, involving the transient chemoselective formation of covalent bonds with the constituents of cell membranes. While DCvC has already attracted interest in material sciences, the recent results described in this Account showcase the vast potential of DCvC in biological sciences, and in particular in delivery applications where self-fabricated, adaptive, and responsive devices are of utmost importance.
递呈仍然是限制小分子药物和新型生物制剂潜力的主要障碍,这些药物如果没有载体的帮助,就不容易进入细胞。一个成功的主动递呈过程涉及三个步骤:(a)用载体标记药物,(b)有效穿过生物屏障运输这种[药物-载体]缀合物,最后(c)控制药物释放。虽然共价键形成和/或超分子缔合涉及[药物-载体]缀合物的形成,但最后一步需要精确的受控解离,以触发药物释放。因此,为了追求智能、有效和无毒的递呈系统,人们已经广泛认识到,对动态自组装的控制可以释放人工载体的功效。在本报告中,我讨论了我们和同事们最近在递呈应用中实施动态共价化学(DCvC)的努力。DCvC 利用可逆共价反应来生成可以自我制造、自适应、响应和受控方式分解的共价系统。在从事递呈应用的研究社区中,已经出现了一组特权的可逆共价反应,其基础是缩合反应(亚胺、酰腙、肟)和二硫键和硼酸酯的形成。讨论了使这种化学特别适合这种 DCvC 方法的最新发展。基于使用这种可逆共价反应提供瞬时[药物-载体]缀合物的原理, justifies 这种化学在递呈中的潜在合理性,这些缀合物可以自发地、选择性地形成,然后在自组装和递呈过程中通过可逆共价键的动态性质自适应和自我修正它们的结构,最后响应物理化学刺激,如 pH 和氧化还原变化,从而实现受控的解离和伴随的药物释放。由于这些原因,DCvC 最近作为一种杠杆工具出现,具有朝着更智能的递呈系统发展的前景。DCvC 的实施可以遵循以下三种方法:(1)动态共价生物缀合物,涉及与载体的瞬时共价缀合,(2)动态共价载体,涉及通过超分子缔合复杂药物的载体的受控动态和自适应组装和拆卸,以及(3)动态共价靶向,涉及与细胞膜成分的瞬时化学选择性共价键形成。虽然 DCvC 已经在材料科学中引起了关注,但本报告中描述的最新结果展示了 DCvC 在生物科学中的巨大潜力,特别是在自我制造、自适应和响应性设备至关重要的递呈应用中。